Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy February 2, 2023 09:15 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
